Description
TB-500 10mg is a lyophilised research-peptide product supplied as one sealed vial labelled 10mg. Its literature requires care with terminology: material called TB-500, the acetylated seven-residue fragment Ac-LKKTETQ, the unacetylated fragment LKKTETQ and the 43-residue full-length thymosin beta-4 are not all the same molecule. This product page distinguishes what has been measured in those research systems from what must be verified for the supplied lot. 1 2
For in-vitro laboratory research only; not for human or veterinary use. Current price and stock are displayed by the native purchase panel. Request batch documentation before ordering if the exact peptide form is important to your method.
TB-500 10mg: the item supplied
| Attribute | This catalogue record |
|---|---|
| Product name | TB-500 10mg |
| Labelled quantity | 10mg total per vial |
| Supplied form | Lyophilised powder, sealed vial |
| Related research family | Thymosin beta-4-derived peptide fragments |
| Exact sequence, salt, terminal form | To be established using the relevant material specification and lot report—not inferred from the commercial name |
| Price and availability | Current live WooCommerce purchase panel |
A literature name is not an analytical specification. In 2012, Esposito and colleagues identified Ac-LKKTETQ in a particular product sold as TB-500 using chromatographic separation and high-resolution mass spectrometry. That result is informative for terminology, but it does not certify the contents of this Core Research vial. An identity report applicable to the actual lot should resolve the molecular form before any sequence, CAS number or theoretical molecular weight is attached to the supplied material. 1
Choose the correct related product
The TB-500 Refill 10mg and TB-500 10mg Pen are separate presentations. The BPC-157 / TB-500 Blend 10mg is a different composition: 5mg BPC-157 plus 5mg TB-500, not 10mg of TB-500 alone. The single-material versus blend guide explains the additional variables introduced by a mixture.
Why researchers investigate thymosin beta-4-related fragments
Full-length thymosin beta-4 is studied in part because of its interactions with actin, a protein that helps form the cell’s internal scaffold. Actin assembly influences shape, adhesion and movement; changes in these processes are measured in cell migration and repair models. A short sequence containing an actin-interacting region can be a useful research probe, but a shared motif is not proof that a seven-residue fragment reproduces the entire parent molecule’s biochemical behaviour.
Which residues matter for actin binding?
Van Troys and colleagues used chemically synthesised full-length thymosin beta-4 variants, cross-linking, native-gel complexes and actin-sequestering assays. Their mutational analysis identified contributions from the N-terminal region and a separate motif around residues 17–22. This matters because the LKKTETQ region is part of the full-length sequence’s interaction architecture, not a complete replacement for every structural contact in the parent protein. 2
What did animal skin-repair experiments report?
Philp and colleagues studied full-length thymosin beta-4 and a synthetic peptide containing its actin-binding domain in animal dermal-wound models. They observed faster healing-related endpoints in aged mice and changes in wound contraction or collagen deposition in particular settings. Importantly, the published fragment in these experiments was LKKTETQ, not automatically the acetylated Ac-LKKTETQ reference. A result in aged mouse skin cannot be transferred unchanged to a differently specified lyophilised research vial. 3
Do all cell models show increased migration?
No. Shah and colleagues studied human hepatic stellate cells exposed to PDGF-BB and reported that thymosin beta-4 and actin-binding-domain-related interventions reduced activation, proliferation and migration in that stimulated system. This differs from increased migration discussed in some wound-model research. The apparently opposing directions reflect different biological questions, cells, stimulants and outcome measures rather than a universal instruction to increase cell movement. 4
A key distinction: TB-500 parent peptide versus metabolites
Rahaman and colleagues (2024) developed an analytical method for Ac-LKKTETQ and its metabolites in experimental samples, including serum and animal material. In their fibroblast wound-healing screen, Ac-LKKTE, one of the metabolites, was the only tested material that showed significant wound-healing activity compared with control. That positive metabolite result must not be reassigned to the parent Ac-LKKTETQ simply because they share the TB-500 research label. 5
| Material in the literature | Distinction that changes interpretation |
|---|---|
| Full-length thymosin beta-4 | 43-residue parent; several regions can contribute to actin interactions |
| LKKTETQ | Unacetylated seven-residue motif used in some animal and cellular studies |
| Ac-LKKTETQ | N-terminally acetylated fragment identified in specific TB-500 analytical research |
| Ac-LKKTE and other metabolites | Breakdown products with separately measured persistence and biological endpoints |
| This TB-500 10mg vial | Actual identity and lot results require Core Research’s applicable specification/report |
Research interpretation: the biochemical identity, model, formulation and tested endpoint must travel together with a study’s conclusion. A paper about a related fragment is useful for understanding the literature; it is not a substitute for a source-material identity test.
Batch documentation and analytical questions
Before purchasing, request a batch-specific document using “TB-500 10mg, lyophilised vial”. Ask whether the report identifies the peptide’s exact sequence/terminal modification, chromatographic method, corresponding mass-spectrum species and measured content when available. After delivery, match the certificate to the lot on the container and retain the order identifier.
A report’s HPLC percentage concerns the chromatographic method and the defined basis of the result. A mass-spectrum identification is a different measurement; neither alone establishes the nominal mass of material supplied or sterility. The HPLC explanation, mass-spectrometry guide and CoA-reading guide explain how to distinguish those claims.
This page does not claim that a specific current lot has been tested at a particular purity, that every analytical method is available, or that another seller’s certificate validates this item.
Storage, receiving and UK ordering
Follow the supplied vial’s label and applicable batch-specific storage information. Dry lyophilised material and a prepared solution are not the same stability case; solvent, concentration, container and actual exposure history can change laboratory stability. The storage guide provides selection criteria without promising an unverified expiry or post-preparation lifetime.
On receipt, compare the labelled material, quantity, packaging and lot with the order. Keep photographs and shipment details if the parcel arrives visibly damaged, unexpectedly warm or delayed, and follow the receiving checklist and arrival-condition guidance.
Core Research’s published shipping policy states that it dispatches from Birmingham, UK, with plain outer packaging and tracking details where provided. Actual charges and delivery estimates depend on the order and destination; the purchase panel and checkout supply current price, stock and totals. For university or laboratory quotations, the institutional procurement route handles enquiries without assuming a guaranteed lot reservation.
TB-500 product questions
Does TB-500 10mg contain BPC-157?
Not in this standalone product’s listed composition. BPC-157 is separately named in the 5mg+5mg blend. Read the composition field, not just the combined “10mg” label.
Does the TB-500 name mean the vial contains full-length thymosin beta-4?
No reliable chemical-form conclusion follows from the trade name alone. The primary literature distinguishes full-length thymosin beta-4, LKKTETQ, acetylated Ac-LKKTETQ and metabolites. The supplied vial requires applicable analytical identity documentation.
Can I request information before buying?
Yes. Use Batch Documentation and identify the precise vial. A pre-purchase enquiry does not require an existing lot number, but a report for a different lot cannot be treated as proof of the eventual supplied batch.
What if my delivered vial or report looks inconsistent?
Contact Core Research promptly with the order, item, container lot and clear photographs. Retain the material and documents for reconciliation before laboratory use.
Research references
[1] Esposito S et al. (2012). Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500. Drug Testing and Analysis. DOI: 10.1002/dta.1402.
[2] Van Troys M et al. (1996). The actin binding site of thymosin beta 4 mapped by mutational analysis. EMBO Journal 15:201–210.
[3] Philp D et al. (2003). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration.
[4] Shah R et al. (2018). Thymosin β4 inhibits PDGF-BB induced activation, proliferation, and migration of human hepatic stellate cells via its actin-binding domain. Expert Opinion on Biological Therapy.
[5] Rahaman KA et al. (2024). Simultaneous quantification of TB-500 and its metabolites and screening by wound healing activities in vitro. Journal of Chromatography B.




